Anti-IL-5 Antibody Pharmacokinetics for Eosinophil Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by IL-5 and excess eosinophil production, such as asthma, are limited by the side effects of corticosteroids and the ineffectiveness of alternative anti-inflammatory drugs, necessitating a more targeted approach to reduce eosinophil levels.
Innovation Solution
Administration of anti-IL-5 antibodies that achieve a mean maximum plasma concentration of at least 1.03 ± 0.21 µg/mL and an Area Under the Curve value of at least 15.5 ± 2.7 µg×day/mL, specifically targeting IL-5 to inhibit eosinophil stimulation and reduce eosinophil counts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If corticosteroids are used to suppress eosinophil numbers, then eosinophil levels are reduced, but side effects increase
Solution Approach 1:
The patent introduces anti-IL-5 antibodies as an intermediary substance that specifically binds to and neutralizes IL-5, thereby blocking the signaling pathway that leads to eosinophil production. This mediator approach allows eosinophil suppression without using corticosteroids, avoiding their harmful side effects while achieving the desired therapeutic effect on eosinophil numbers
Solution Approach 2:
The patent extracts and targets the specific pathological mechanism (IL-5 signaling) that drives eosinophil production, rather than using broad-spectrum corticosteroids that suppress all inflammatory pathways. By isolating and blocking only the IL-5 pathway with monoclonal antibodies, the treatment achieves eosinophil reduction while preserving other immune functions and avoiding corticosteroid side effects
2Reliability
If cromoglycates are used as anti-inflammatory therapy, then treatment is provided, but effectiveness is reduced
Solution Approach 1:
The patent changes the therapeutic parameter from non-specific anti-inflammatory agents (cromoglycates) to highly specific biologics (anti-IL-5 antibodies) with defined pharmacokinetic and pharmacodynamic parameters. This parameter change includes achieving specific plasma concentration ranges and AUC values that ensure reliable and effective eosinophil suppression, dramatically improving clinical efficacy compared to cromoglycate therapy
Data Source
AI summary
The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03 ± 0.21 μg/mL, an Area Under the Curve value of at least about 15.5 ± 2.7 μg/day/mL and a serum half-life of about 16.2 ± 2.1 days to about 21.7 ± 2.8 days.